<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336464">
  <stage>Registered</stage>
  <submitdate>8/02/2011</submitdate>
  <approvaldate>11/02/2011</approvaldate>
  <actrnumber>ACTRN12611000165987</actrnumber>
  <trial_identification>
    <studytitle>Microarray analysis following Anti-Inflammatory Interventions in Chronic Obstructive Pulmonary Disease (COPD)</studytitle>
    <scientifictitle>The use of microarray analysis to examine the effects of an anti-inflammatory intervention containing statins, lycopene and fish oil in COPD.</scientifictitle>
    <utrn />
    <trialacronym>MAID Study</trialacronym>
    <secondaryid>This trial does not have a secondary ID</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Pulmonary Disease</healthcondition>
    <healthcondition>Ex-smokers with obstructive airway disease</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral Simvastatin 40mg (1 tablet daily for 12 weeks) with the addition of  oral fish oil  (DHA 200mg, EPA 300mg) 1g and oral lycomato (lycopene supplement) 500mg capsules (3 x capsules daily for 8 weeks) at week 4.</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Using microarray analysis, sputum mRNA expression data</outcome>
      <timepoint>0, 4 and 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Ex-smokers with a smoking history of a least 10 pack years, obstructive airway disease (FEV1/FVC ratio &lt; 2SD below expected value for age, sex and height)</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Currently taking lipid lowering drugs or drugs that interact with statins, Subjects with active liver disease, renal impairment, cardiovascular disease, pregnant or breast feeding, subjects with known allergies or intolerance to statins or one of the dietary supplements</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Subjects who are eligible for the study will be invited to attend a screening visit. If eligible, they will be entered into the study. All subjects will receive the study intervention with no randomisation method to be employed.</concealment>
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Sequential design</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/03/2011</anticipatedstartdate>
    <actualstartdate>1/06/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Suspended</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Hunter New England Health Service</primarysponsorname>
    <primarysponsoraddress>John Hunter Hospital
Lookout Road
New Lambton Heights NSW 2305</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Woolcock Institute of Medical Research - NHMRC CCRE Seed Project</fundingname>
      <fundingaddress>PO Box M77
Missenden Road
Camperdown NSW 2050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Newcastle</sponsorname>
      <sponsoraddress>University Drive
Callaghan NSW 2308</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will use microarray analysis to investigate the effects of statins, antioxidant nutrients and omega-3 fatty acids (fish oil) in COPD. COPD is a condition that involves inflammation of the airways that can cause scarring and airflow limitation of the lung, with the primary cause being cigarette smoking. Statins are drugs which are usually used to lower cholesterol levels but are also known to have anti-inflammatory and possible antioxidant effects. Omega-3 fatty acids and antioxidants have also been found to be useful in reducing inflammation. 
Hypothesis: Statins, antioxidants and fish oil supplements may have different and potentially complementary effects, on genes involved in inflammatory pathways. The combined use of these interventions may provide a superior approach to reducing inflammation and slowing deterioration of lung function in ex-smokers with obstructive airway disease.</summary>
    <trialwebsite>Nil</trialwebsite>
    <publication>Nil</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Human Research Ethics Committee</ethicname>
      <ethicaddress>Lookout Road
New Lambton Heights NSW 2305</ethicaddress>
      <ethicapprovaldate>1/03/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>28/01/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Wood</name>
      <address>Centre for Asthma and Respiratory Diseases
Level 2, West Wing, HMRI Building
Kookaburra Crt
New Lambton Heights, NSW, 2305
</address>
      <phone>+61 2 40420147</phone>
      <fax>+61 2 40420046</fax>
      <email>lisa.wood@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Joanne Smart</name>
      <address>Centre for Asthma and Respiratory Diseases
Level 2, West Wing, HMRI Building
Kookaburra Crt
New Lambton Heights, NSW, 2305
</address>
      <phone>+61 2 40143947</phone>
      <fax>+61 2 40143945</fax>
      <email>joanne.smart@calvarymater.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Joanne Smart</name>
      <address>Centre for Asthma and Respiratory Diseases
Level 2, West Wing, HMRI Building
Kookaburra Crt
New Lambton Heights, NSW, 2305
</address>
      <phone>+ 61 2 40143947</phone>
      <fax>+ 61 2 40143945</fax>
      <email>joanne.smart@calvarymater.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Wood</name>
      <address>Centre for Asthma and Respiratory Diseases
Level 2, West Wing, HMRI Building
Kookaburra Crt
New Lambton Heights, NSW, 2305
</address>
      <phone> +61 2 40420147</phone>
      <fax />
      <email>lisa.wood@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>